Table 1.
Demographic and Clinical Characteristics of Participants.
| Measure | HC (n = 30) | FEP 0 (n = 32) | FEP 1 (n = 24) | p value (HC vs. FEP 0) | p value (HC vs. FEP 1) | p value (FEP 0 vs. FEP 1) |
|---|---|---|---|---|---|---|
| Age (Years) | 27.1 (4.3) | 26.8 (6.1) | 27.0 (5.8) | 0.823a | 0.962a | |
| Sex (Female/Male) | 15/15 | 16/16 | 12/12 | 1.000b | 1.000b | |
| Education (Years) | 14.3 (2.4) | 13.0 (3.2) | 13.4 (3.1) | 0.310c | 0.822c | |
| Handedness (Right/Left) | 30/0 | 32/0 | 24/0 | 1b | 1b | |
| Current tobacco use (yes/no) | 8/22 | 3/29 | 2/22 | 0.057b | 0.157b | |
| Current cannabis use (yes/no) | 0/30 | 0/32 | 0/24 | 1b | 1b | |
| DUP (Months) | NA | 7.2 (12.4) | 6.7 (12.2) | |||
| PANSS Total | NA | 73.8 (18.2) | 48.6 (14.1) | < 0.001d | ||
| PANSS Positive | NA | 20.3 (5.3) | 10.9 (3.6) | < 0.001d | ||
| PANSS Negative | NA | 16.9 (6.1) | 12.7 (5.0) | < 0.001d | ||
| PANSS General | NA | 36.7 (9.9) | 24.7 (6.8) | < 0.001d | ||
| CGI | NA | 4.8 (0.9) | 3.0 (1.1) | < 0.001d | ||
| CPZ eq (mg/day) | NA | NA | 335.4 (140.2) |
Note: Values are presented as mean (SD). Abbreviations: HC, healthy control; FEP 0, drug-naïve first-episode psychosis; FEP 1, first-episode psychosis patients at 8 weeks post treatment; DUP, duration of untreated psychosis; PANSS, Positive and Negative Syndrome Scale; CGI, clinical global impression; CPZ eq, chlorpromazine equivalence.
a
Independent two-sample t-test.
b
Chi-square test.
c
Mann-Whitney U test.
d
Wilcoxon signed-rank test.